SPDR S&P Kensho New Economies Composite ETF (ARCA: KOMP)

Últimas noticias sobre SPDR S&P Kensho New Economies Composite ETF (ARCA:KOMP)

Technology

Industrials

Healthcare

Financial Services

Communication Services

Consumer Cyclical

Basic Materials

Utilities

Energy

Other

Consumer Defensive

Under normal market conditions, the fund generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index is designed to capture companies whose products and services are driving innovation and transforming the global economy through the use of existing and emerging technologies, and rapid developments in robotics, automation, artificial intelligence, connectedness and processing power. The fund is non-diversified.

Oceaneering International Inc

Teledyne Technologies Inc

Parsons Corporation Com

Bruker Corp.

Coinbase Global, Inc.

Kratos Defense & Security Solutions, Inc.

Lockheed Martin Corp

Leidos Holdings, Inc.

Paysafe Ltd

Aerovironment Inc

Elbit Systems

Lexinfintech Holdings Ltd

Osi Systems Inc

Irhythm Technologies, Inc.

Ehang Holdings Ltd

Intuitive Machines Inc A

Masimo Corp

Elbit Systems Ltd

Northrop Grumman Corp.

SPDR S&P Kensho New Economies Composite ETF

Equities

News

Sports Betting

Small Cap

Movers

General

Gabelli ETFs Trust Gabelli Financial Services Opportunities ETF

GABF

KOMP

PSFE

Paysafe consigue la aprobación del Banco Central de Brasil para operar en el mercado regulado de apuestas deportivas y juegos online.

Paysafe obtiene licencia en Brasil y fortalece su presencia en iGaming

JMP Securities analyst Jordan Bender maintains Caesars Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) with a Market Outperform and lowers the price target from $53 to $45.

Price Target

Analyst Ratings

JMP Securities Maintains Market Outperform on Caesars Entertainment, Lowers Price Target to $45

Truist Securities analyst Michael Ciarmoli maintains Moog (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOG#NYSE">MOG</a>) with a Buy and lowers the price target from $237 to $215.

MOG/A

Truist Securities Maintains Buy on Moog, Lowers Price Target to $215

U.S. stocks were lower, with the Dow Jones index falling around 550 points on Thursday.
Shares of uniQure N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) rose sharply during Thursday's session after the company was granted FDA granted Breakthrough Therapy designation for AMT-130 for the treatment of <a href="https://www.benzinga.com/quote/QURE">Huntington&#8217;s disease.</a>
uniQure shares jumped 45.3% to $13.65 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Structure Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) gained 21.4% to $22.49.</li>
<li>Hertz Global Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) rose 20.3% to $6.99 after Pershing Square Capital Management disclosed a stake via a 13F. CNBC reported that Pershing Square&#8217;s stake is 19.8%, through shares &amp; swaps.</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) gained 15.3% to $847.08 after the company announced topline Phase 3 results from its ACHIEVE-1 trial, which showed orforglipron demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) rose 13.8% to $10.97.</li>
<li>ClearPoint Neuro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) gained 13% to $13.02.</li>
<li>VersaBank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBNK#NASDAQ">VBNK</a>) rose 12% to $10.91.</li>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) jumped 10.7% to $3.6200 following FY24 financial results.</li>
<li>Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) gained 10.1% to $80.00. The move came as investors responded to news that billionaire investor Bill Ackman&#8217;s Pershing Square Capital Management significantly increased its stake in Hertz Global Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>).</li>
<li>Insteel Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIIN#NYSE">IIIN</a>) gained 9.1% to $29.15 following second-quarter results.</li>
<li>Fidelity National Information Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) shares jumped 7% to $73.41. Fidelity National Information Services unveiled two strategic moves—acquiring Global Payments' Issuer Solutions unit and selling its remaining stake in Worldpay.</li>
<li>Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) gained 4.4% to $76.40.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44862443/intuit-to-rally-around-19-here-are-10-top-analyst-forecasts-for-thursday">Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

Trading Ideas

CAPR

CLPT

DLTR

GPCR

IIIN

QURE

VBNK

uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday

JMP Securities analyst Trevor Cranston maintains Two Harbors Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWO#NYSE">TWO</a>) with a Market Outperform and lowers the price target from $14 to $13.5.

JMP Securities Maintains Market Outperform on Two Harbors Inv, Lowers Price Target to $13.5

Truist Securities analyst Youssef Squali maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and lowers the price target from $770 to $700.

Truist Securities Maintains Buy on Meta Platforms, Lowers Price Target to $700

Macro Economic Events

Econ #s

Economics

USA Natural Gas Storage 16B Vs 24B Est.; 57B Prior

American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) has outperformed the market over the past 20 years by 5.71% on an annualized basis producing an average annual return of 13.62%. Currently, American Tower has a market capitalization of $103.72 billion. 
Buying $1000 In AMT: If an investor had bought $1000 of AMT stock 20 years ago, it would be worth $12,964.89 today based on a price of $221.57 for AMT at the time of writing.
<h3>American Tower's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744900212_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In American Tower 20 Years Ago Would Be Worth This Much Today

JMP Securities analyst Trevor Cranston maintains Redwood Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RWT#NYSE">RWT</a>) with a Market Outperform and lowers the price target from $8 to $7.5.

JMP Securities Maintains Market Outperform on Redwood Trust, Lowers Price Target to $7.5

Truist Securities analyst Michael Ciarmoli maintains Leonardo DRS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRS#NASDAQ">DRS</a>) with a Buy and raises the price target from $37 to $40.

Truist Securities Maintains Buy on Leonardo DRS, Raises Price Target to $40

Defiance ETFs has bolstered its portfolio of leveraged <a href="https://www.benzinga.com/etfs">single-stock ETFs</a>.
Two new products debuted last week: the Defiance Daily Target 2X Long RGTI ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTX#NASDAQ">RGTX</a>) and the Defiance Daily Target 2X Short SMCI ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCZ#NASDAQ">SMCZ</a>). They aim to provide traders with leveraged, tactical access to two of the market&#8217;s most story-oriented tech stocks.
RGTX provides 2x daily leveraged exposure to quantum computing player Rigetti Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>). This ETF is designed for investors looking for amplified upside potential in a hot and early-stage theme. Conversely, SMCZ provides 2x inverse exposure to Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), a soaring AI infrastructure stock, for those interested in tactically hedging or profiting from possible pullbacks.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/04/44854262/chipwrecked-nvidias-export-ban-triggers-etf-meltdown-and-one-big-winner">Chipwrecked: Nvidia&#8217;s Export Ban Triggers ETF Meltdown (And One Big Winner)</a>
Speaking to Defiance ETFs CEO Sylvia Jablonski helped us understand the strategic timing and thematic underpinnings behind these launches.
"We're seeing significant investor interest in expressing tactical views on high-beta, thematically relevant stocks," Jablonski said. 
Rigetti represents early-stage exposure to quantum computing, while Super Micro is one of the most talked-about AI infrastructure names. These ETFs give traders precision tools to either amplify bullish conviction or tactically hedge in a highly narrative-driven market."
Rigetti, while yet to enter the late innings of quantum growth, is one of a handful of pure-play public plays in the field.
<a href="https://www.globenewswire.com/news-release/2025/04/01/3053097/0/en/defiance-launches-rgtx-2x-leveraged-etf-for-rigetti-computing-inc.html">RGTX</a>, as named by Jablonski, enables investors to &#8220;express outsized conviction&#8221; in a ticker that may proportionally gain the most from the next round of speculative thematic rotation—especially with attention piquing on what may follow AI as the next big tech disruption.
Conversely, <a href="https://www.globenewswire.com/news-release/2025/04/01/3053305/0/en/defiance-launches-smcz-2x-short-etf-for-super-micro-computer-inc.html">SMCI </a>has skyrocketed in 2024 on the strength of AI-driven demand for high-performance computing. But its astronomical ascent has also generated doubts. 
&#8220;We noticed a growing chorus of investors seeking to hedge or fade what they view as overextended price action,&#8221; Jablonski said. The SMCZ ETF is geared toward those anticipating mean reversion or earnings-driven volatility without the hassle of shorting.
Jablonski highlighted the fact that ETFs fit within the larger macro theme: &#8220;Both products capture distinct investor behaviors: chasing early-stage innovation (RGTX) and hedging against frothy AI sentiment (SMCZ).&#8221; In a market characterized by uncertainty around rates and high-volatility tech, leveraged ETFs provide weapons to trade rotating themes with accuracy and agility.
While acknowledging concerns about leveraged product suitability in an environment where rate cuts may be delayed further, Jablonski stressed that RGTX and SMCZ are geared toward sophisticated, short-term traders. &#8220;These names will likely continue to exhibit extreme sensitivity to macro signals. While delayed cuts may compress valuations, volatility creates both opportunity and risk. Leveraged ETFs like RGTX and SMCZ are tools designed for short-term traders navigating exactly this environment of heightened uncertainty and rotating narratives.&#8221;
During the first week of trading, Defiance has closely followed liquidity, volume, and correlation to volatility. Jablonski reported &#8220;strong trader interest and responsive price action,&#8221; indicating genuine hunger for strategic positioning in both quantum computing and AI infrastructure stories.
As AI starts to age and gain valuation worries, quantum computing may be next in vogue for speculative investor interest. &#8220;Quantum computing sits at that intersection of scientific ambition and speculative upside,&#8221; Jablonski stated. &#8220;While the technology is early, public names like Rigetti offer rare, liquid access to a transformational theme—and traders want optionality on that.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44843179/the-dividend-etf-that-just-woke-up-and-why-investors-are-watching-closely">The Dividend ETF That Just Woke Up And Why Investors Are Watching Closely</a></li>
</ul>
Image: Shutterstock

New ETFs

Interview

ETFs

RGTI

RGTX

SMCI

SMCZ

EXCLUSIVE: Why Defiance Is Letting You Go 2X Long On Quantum, And 2X Short On AI, Straight From The CEO

Truist Securities analyst Michael Ciarmoli maintains L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) with a Buy and lowers the price target from $274 to $264.

Truist Securities Maintains Buy on L3Harris Technologies, Lowers Price Target to $264

Truist Securities analyst Michael Ciarmoli maintains Kratos Defense &amp; Security (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) with a Buy and raises the price target from $32 to $38.

KTOS

Truist Securities Maintains Buy on Kratos Defense & Security, Raises Price Target to $38

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to uniQure N.V.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) AMT-130 <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">for Huntington&#8217;s disease</a> on Thursday
This designation is in addition to the Regenerative Medicine Advanced Therapy (RMAT) designation, the Orphan Drug designation and the Fast Track designation, all of which were previously granted <a href="https://www.benzinga.com/pressreleases/25/04/g44860315/uniqure-announces-fda-breakthrough-therapy-designation-granted-to-amt-130-for-the-treatment-of-hun" target="_blank" rel="noreferrer noopener">by the FDA to AMT-130</a>.
Huntington&#8217;s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms, including chorea, behavioral abnormalities and cognitive decline, resulting in progressive physical and mental deterioration.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43569013/uniqure-csl-behrings-hemophilia-gene-therapy-shows-sustained-efficacy-and-safety-at-four-years" rel="noreferrer noopener">uniQure/ CSL Behring&#8217;s Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years</a>
According to a 2021 study in Neuroepidemiology, approximately 70,000 people have been diagnosed with Huntington&#8217;s disease in the U.S. and Europe.
The Breakthrough Therapy designation is supported by clinical data from the ongoing Phase 1/2 trials of AMT-130 for Huntington&#8217;s disease.
In July 2024, uniQure presented interim data at 24 months, showing dose-dependent slowing of disease progression based on the cUHDRS in treated patients compared to a propensity-weighted natural history. To date, 45 patients have received AMT-130.
The Breakthrough Therapy designation is intended to expedite the development and review of investigational therapeutic candidates for treating a serious condition. Preliminary clinical evidence suggests that the drug may show substantial improvement over available therapy on one or more clinically significant endpoints.
In general, the preliminary clinical evidence should show a clear advantage over available therapy. A drug with Breakthrough Therapy designation is eligible for all Fast Track designation features and intensive guidance on an efficient drug development program.
<h2 class="wp-block-heading">uniQure Stock Predication For 2025</h2>
Equity research analysts, both on and off Wall Street, typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at uniQure, an investor could make an assessment of a stock's long-term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many consider a bullish signal, they can extrapolate that trend into the future using a trendline. For uniQure, the 200-day moving average sits at $9.61, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is above the current price of $9.39. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors can use trend lines to make an educated guess about where a stock might trade in the future if conditions remain stable.
Price Action: QURE stock is up 49.8% at $14.07 during the premarket session at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/04/44852229/interactive-brokers-misses-q1-earnings-analyst-flags-weaker-securities-lending-revenue" target="_blank" rel="noreferrer noopener">Interactive Brokers Misses Q1 Earnings: Analyst Flags Weaker Securities Lending Revenue</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?

JMP Securities analyst Trevor Cranston maintains MFA Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MFA#NYSE">MFA</a>) with a Market Outperform and lowers the price target from $12.5 to $12.

JMP Securities Maintains Market Outperform on MFA Finl, Lowers Price Target to $12

Truist Securities analyst Lucas Pipes maintains JB Hunt Transport Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) with a Hold and lowers the price target from $165 to $130.

JBHT

Truist Securities Maintains Hold on JB Hunt Transport Servs, Lowers Price Target to $130

IPOs

Chagee Holdings Indicating $41 On 108,349 Shares

JMP Securities analyst Silvan Tuerkcan reiterates Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Market Outperform and maintains $41 price target.

Reiteration

EXEL

JMP Securities Reiterates Market Outperform on Exelixis, Maintains $41 Price Target

Truist Securities analyst Michael Ciarmoli maintains Howmet Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) with a Buy and lowers the price target from $140 to $136.

Truist Securities Maintains Buy on Howmet Aerospace, Lowers Price Target to $136

Midi Health, a rising player in women&#8217;s healthcare, just closed a $63 million Series B funding round with <a href="https://www.benzinga.com/general/entertainment/25/01/42962518/meghan-markle-netflix-delay-launch-of-cooking-reality-show-after-california-fires-focus-on-the-needs-of-those-impacted">Meghan Markle</a> joining a star-powered list of <a href="https://in.benzinga.com/personal-finance/25/03/44374276/reddit-explodes-over-dividend-math-how-much-would-the-annual-dividend-be-for-a-280k-investment-investors-debate-schds-future-growth">investors</a>. The virtual healthcare startup, focused on menopause and midlife health support, also gained backing from names like comedian Amy Schumer, &#8220;White Lotus&#8221; star Connie Britton, and fashion icon Tory Burch.
The investment marks another strategic move for Markle, who has spent the past five years quietly building a portfolio focused on purpose-driven companies with female leadership at the forefront. According to<a href="https://techcrunch.com/2025/04/10/meghan-markle-has-made-another-angel-investment/"> TechCrunch</a>, other investors in this latest round include Laurene Powell Jobs' Emerson Collective and G9 Ventures. Other major figures from companies like OpenAI, Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>, GOOG)), Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)​, and Meta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) have also invested in Midi Health.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>Invest in the future of digital engagement: <a href="https://www.benzinga.com/money/vatom-adv">Own a piece of the $100 billion Metaverse for just $500</a>.</li>
</ul>
<h2 class="wp-block-heading">How Meghan Markle Is Quietly Redefining Women's Entrepreneurship</h2>
Midi Health offers digital clinical care for women aged 35 and over, addressing menopause symptoms and other midlife health concerns. The company aims to close the major gap in healthcare options for this demographic. About 40% of Midi's team identifies as people of color, reinforcing the company&#8217;s commitment to providing culturally responsive care.
Speaking to<a href="https://fortune.com/2025/04/08/duchess-meghan-founder-confessions-podcast-launch-as-ever-consumer-products/"> Fortune</a>, Markle encouraged women to engage more openly with finance. "Women need to see that they can build," she said. "Women don't need to be afraid to talk about finance. And I think the more financial literacy we have, the stronger we're going to be."
The Series B round saw 80 investors contributing between $10,000 and $500,000 each, with a clear focus on aligning with Midi Health's mission to empower women. In a<a href="https://www.prnewswire.com/news-releases/women-leaders-across-tech-entertainment-sports-media-and-fashion-come-together-to-invest-in-midi-health-302253241.html"> statement</a>, Midi Health highlighted that the group of investors included women leaders from industries spanning entertainment, professional sports, media, technology, and business.
Trending: With shares starting at $1.52, <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">this could be your chance to invest in the future of healthcare</a>.
<h2 class="wp-block-heading">Meghan Markle's Investment Map</h2>
Markle's growing angel investment portfolio now spans over ten companies, with a strong emphasis on brands led by women and those prioritizing wellness, health, and education. Previous investments include wellness-focused companies like Clevr, a beverage brand she's supported since 2020, and Highbrow Hippie.
Midi Health's service model is structured for both insured and self-paying patients. The startup&#8217;s virtual care system is designed to make expert menopause support more accessible to women across the U.S., offering personalized treatment plans through a team of specialized clinicians.
Markle's partnership with Midi Health comes at a time when women's health startups are gaining more attention from both investors and the public. According to a Silicon Valley Bank<a href="https://www.svb.com/trends-insights/reports/womens-health-report/"> report</a>, women's health investment hit $2.6 billion last year, surpassing 2023's total by nearly $1 billion. The startup's strategic growth aligns with broader market trends pushing for better healthcare solutions tailored to women's specific needs.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
<h2 class="wp-block-heading">Building A New Empire Across The Atlantic</h2>
Since relocating to the U.S. and stepping away from royal duties, Markle and her husband, Prince Harry, have been steadily building a business presence, investing significant sums into various American startups. Their portfolio reflects a vision of supporting companies that drive social impact and champion underrepresented communities.
Midi Health&#8217;s latest funding round secures the company&#8217;s future growth and also signals a larger shift in the healthcare landscape. With names like Markle leading the way, the conversation around women&#8217;s midlife health is finally taking center stage.
Read Next:
<ul>
<li>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

AAPL

AMZN

GOOGL

Meghan Markle Invests In $63M Midi Health Round As Top Women From OpenAI, Google, Meta, And Hollywood Rally Behind Menopause Care

Truist Securities analyst Michael Ciarmoli maintains Hexcel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) with a Buy and lowers the price target from $80 to $73.

Truist Securities Maintains Buy on Hexcel, Lowers Price Target to $73

Comments

SPDR S&P Kensho New Economies Composite ETF

Noticias

Últimas noticias sobre SPDR S&P Kensho New Economies Composite ETF (ARCA:KOMP)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL